Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International Off-Patent Industry's Wishlist For WHO Pandemic Accord

Executive Summary

As the WHO seeks input on a global accord to strengthen pandemic preparedness, the IGBA has provided suggestions from the off-patent industry ahead of a key step in the drafting process later this month.

You may also be interested in...

Teva Wraps Up Nationwide US Opioids Settlement

Teva has formally concluded its nationwide settlement agreement over opioids litigation in the US with all 50 states – including holdout Nevada – removing a significant legal overhang for the company.

Murphy Named As OGD Director At US FDA

The FDA has announced that agency veteran Iilun Murphy will take over leadership of its Office of Generic Drugs. At the same time, CDER principal deputy center director and chair of the GDUFA steering committee Jacqueline Corrigan-Curay will assume oversight of OGD and the FDA’s generics program.

Samsung Biologics Strikes $400m+ Biosimilars Supply Deal With Pfizer

Samsung Biologics has struck a deal worth over $400m to manufacture multiple biosimilars for Pfizer.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts